Abstract
Retinoic acid and derivatives (retinoids) exert their anti-neoplastic action through three different, though partially overlapping mechanisms: growth-inhibition, cyto-differentiation and apoptosis. Retinoid related molecules (RRMs) are a promising class of synthetic retinoic acid derivatives endowed with selective apoptotic activity on a large variety of leukemic and solid tumor cells. The in vitro apoptotic activity of RRMs translates into in vivo efficacy in a number of experimental models of neoplasia. The prototype of this novel family of cytotoxic agents is CD437, a conformation restricted retinoid originally developed as a selective RARγ agonist. A number of new RRM congeners, including ST1926, MM002, MM11453 and MX-3350-1, have been recently reported in the literature. Some of these compounds have a stronger apoptotic potential, a lower level of toxicity and a better pharmacokinetic profile than CD437. RRMs have a molecular mechanism of action that is entirely different from that of many other known chemotherapeutics. These compounds induce apoptosis in retinoic acid- and multi-drug-resistant neoplastic cells. The apoptotic process triggered by RRMs is independent of p53 activation and proceeds through a novel pathway in which the mitochondrion seems to play a pivotal role. RRMs show only very limited cross-resistance with other classes of chemotherapeutic agents and show synergistic interactions with a number of classical cyto-toxic agents. The article presents a critical overview of the current knowledge on the pharmacology of RRMs focussing on such issues as the spectrum of cytotoxic activity, the molecular mechanisms of action and the pre-clinical basis of clinical development.
Keywords: Retinoid, Apoptotic Agents, mitochondrion, chemotherapeutic, CD437, Oncology
Current Pharmaceutical Design
Title: Retinoid Related Molecules an Emerging Class of Apoptotic Agents with Promising Therapeutic Potential in Oncology: Pharmacological Activity and Mechanisms of Action
Volume: 10 Issue: 4
Author(s): Enrico Garattini, Maurizio Gianni and Mineko Terao
Affiliation:
Keywords: Retinoid, Apoptotic Agents, mitochondrion, chemotherapeutic, CD437, Oncology
Abstract: Retinoic acid and derivatives (retinoids) exert their anti-neoplastic action through three different, though partially overlapping mechanisms: growth-inhibition, cyto-differentiation and apoptosis. Retinoid related molecules (RRMs) are a promising class of synthetic retinoic acid derivatives endowed with selective apoptotic activity on a large variety of leukemic and solid tumor cells. The in vitro apoptotic activity of RRMs translates into in vivo efficacy in a number of experimental models of neoplasia. The prototype of this novel family of cytotoxic agents is CD437, a conformation restricted retinoid originally developed as a selective RARγ agonist. A number of new RRM congeners, including ST1926, MM002, MM11453 and MX-3350-1, have been recently reported in the literature. Some of these compounds have a stronger apoptotic potential, a lower level of toxicity and a better pharmacokinetic profile than CD437. RRMs have a molecular mechanism of action that is entirely different from that of many other known chemotherapeutics. These compounds induce apoptosis in retinoic acid- and multi-drug-resistant neoplastic cells. The apoptotic process triggered by RRMs is independent of p53 activation and proceeds through a novel pathway in which the mitochondrion seems to play a pivotal role. RRMs show only very limited cross-resistance with other classes of chemotherapeutic agents and show synergistic interactions with a number of classical cyto-toxic agents. The article presents a critical overview of the current knowledge on the pharmacology of RRMs focussing on such issues as the spectrum of cytotoxic activity, the molecular mechanisms of action and the pre-clinical basis of clinical development.
Export Options
About this article
Cite this article as:
Garattini Enrico, Gianni Maurizio and Terao Mineko, Retinoid Related Molecules an Emerging Class of Apoptotic Agents with Promising Therapeutic Potential in Oncology: Pharmacological Activity and Mechanisms of Action, Current Pharmaceutical Design 2004; 10 (4) . https://dx.doi.org/10.2174/1381612043453351
DOI https://dx.doi.org/10.2174/1381612043453351 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells
Current Drug Delivery Artemisia Species as a New Candidate for Diabetes Therapy: A Comprehensive Review
Current Molecular Medicine Altered Hyaluronan Biosynthesis and Cancer Progression: an Immunological Perspective
Mini-Reviews in Medicinal Chemistry Therapeutic Gene Products Delivery by Neuron Stem Cells
Current Pharmaceutical Biotechnology Targeting Apoptotic Signaling Pathways in Human Lung Cancer
Current Cancer Drug Targets Cell-penetrating Peptide-based Intelligent Liposomal Systems for Enhanced Drug Delivery
Current Pharmaceutical Biotechnology Fibroblast Growth Factor Receptor Signaling in Cancer Biology and Treatment
Current Signal Transduction Therapy The Relationship Between Lithium and Cancer Proliferation: A Case-Based Review of the Literature
Current Drug Metabolism Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical Design Pharmacological Activation of p53 in Cancer Cells
Current Pharmaceutical Design Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Current Medicinal Chemistry Glioblastoma Multiforme and its Cell Interruption
Current Cancer Therapy Reviews Mitochondrial VDAC1: Function in Cell Life and Death and a Target for Cancer Therapy
Current Medicinal Chemistry Anti-diabetic Drug Metformin: Challenges and Perspectives for Cancer Therapy
Current Cancer Drug Targets The Targeted-liposome Delivery System of Antitumor Drugs
Current Drug Metabolism Antiangiogenic Resistance: Novel Angiogenesis Axes Uncovered by Antiangiogenic Therapies Research
Current Drug Targets Role of Genetic Factors in Statins Side-Effects
Cardiovascular & Hematological Disorders-Drug Targets Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research Continuous Nanostructures for the Controlled Release of Drugs
Current Pharmaceutical Design Purine Analogues as Kinase Inhibitors: A Review
Recent Patents on Anti-Cancer Drug Discovery